DE69835823D1 - METHOD FOR THE TREATMENT OF PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS WITH CONSENSUS INTERFERON - Google Patents

METHOD FOR THE TREATMENT OF PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS WITH CONSENSUS INTERFERON

Info

Publication number
DE69835823D1
DE69835823D1 DE69835823T DE69835823T DE69835823D1 DE 69835823 D1 DE69835823 D1 DE 69835823D1 DE 69835823 T DE69835823 T DE 69835823T DE 69835823 T DE69835823 T DE 69835823T DE 69835823 D1 DE69835823 D1 DE 69835823D1
Authority
DE
Germany
Prior art keywords
multiple sclerosis
treatment
patients suffering
consensus interferon
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69835823T
Other languages
German (de)
Other versions
DE69835823T2 (en
Inventor
David Martin
Norman L Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DE69835823D1 publication Critical patent/DE69835823D1/en
Application granted granted Critical
Publication of DE69835823T2 publication Critical patent/DE69835823T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention encompasses methods for preventing and treating multiple sclerosis by administering to patients in need thereof a therapeutically effective amount of IFN-con in combination with IL-1ra.
DE69835823T 1997-08-15 1998-07-15 METHOD FOR THE TREATMENT OF PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS WITH CONSENSUS INTERFERON Expired - Lifetime DE69835823T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US911893 1997-08-15
US08/911,893 US6013253A (en) 1997-08-15 1997-08-15 Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
PCT/US1998/014622 WO1999008702A1 (en) 1997-08-15 1998-07-15 Methods for treatment of patients afflicted wih multiple sclerosis using consensus interferon

Publications (2)

Publication Number Publication Date
DE69835823D1 true DE69835823D1 (en) 2006-10-19
DE69835823T2 DE69835823T2 (en) 2007-08-09

Family

ID=25431058

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835823T Expired - Lifetime DE69835823T2 (en) 1997-08-15 1998-07-15 METHOD FOR THE TREATMENT OF PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS WITH CONSENSUS INTERFERON

Country Status (18)

Country Link
US (1) US6013253A (en)
EP (1) EP1003546B1 (en)
JP (1) JP3813440B2 (en)
KR (1) KR100415636B1 (en)
CN (1) CN1183963C (en)
AT (1) ATE338563T1 (en)
AU (1) AU741074B2 (en)
CA (1) CA2299361C (en)
CY (1) CY1107314T1 (en)
DE (1) DE69835823T2 (en)
DK (1) DK1003546T3 (en)
ES (1) ES2267188T3 (en)
HK (1) HK1030157A1 (en)
HU (1) HU229045B1 (en)
IL (2) IL134345A0 (en)
PT (1) PT1003546E (en)
TW (1) TW474817B (en)
WO (1) WO1999008702A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471961B1 (en) * 1999-02-24 2002-10-29 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US20030007972A1 (en) * 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
US7214658B2 (en) * 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US6623736B2 (en) * 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
WO2003049761A1 (en) * 2000-12-08 2003-06-19 Neuronz Limited Use of insuline-like growth factor-i for promoting remyelination of axons
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
ATE435852T1 (en) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd GPE ANALOGUE AND PEPTIDOMIMETICS
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7230167B2 (en) 2001-08-31 2007-06-12 Syngenta Participations Ag Modified Cry3A toxins and nucleic acid sequences coding therefor
ES2289303T3 (en) * 2002-02-06 2008-02-01 Ares Trading S.A. TUMOR NECROSIS FACTOR COMBINED WITH INTERFERON IN DEMELINATING DISEASES.
WO2004035086A2 (en) * 2002-10-16 2004-04-29 Hunter Samuel F Method for treatment of demyelinating central nervous system disease using gm-csf
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
JP4896745B2 (en) 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド Modified human interferon polypeptides and uses thereof
DE102004008168B4 (en) * 2004-02-19 2015-12-10 Voxeljet Ag Method and device for applying fluids and use of the device
EA012205B1 (en) * 2004-05-17 2009-08-28 Арес Трейдинг С.А. Hydrogel interferon formulations
CN1993139B (en) * 2004-06-01 2011-02-16 阿雷斯贸易股份有限公司 Stabilized interferon liquid formulations
WO2005117948A1 (en) 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
BG66458B1 (en) 2005-03-21 2014-10-31 Иван Иванов Agent for concurrent inhibition of endogenous gamma interferon
WO2006119170A2 (en) * 2005-05-02 2006-11-09 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
HUE038947T2 (en) 2005-08-26 2018-12-28 Ares Trading Sa Process for the preparation of glycosylated interferon beta
US8178083B2 (en) * 2005-09-01 2012-05-15 Ares Trading, S.A. Treatment of optic neuritis
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
PT2234645E (en) * 2007-12-20 2012-05-21 Merck Serono Sa Peg-interferon-beta formulations
BG66517B1 (en) 2008-04-08 2016-02-29 Tigo Gmbh Inhibitor of endogenous human interferon - gamma
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
WO2013008102A2 (en) 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Methods and compositions for evaluating and/or treating chronic immune diseases
HUE042463T2 (en) 2013-07-18 2019-07-29 Univ Colorado Regents Composition for the treatment of inflammatory joint disease
BG67190B1 (en) 2017-03-29 2020-11-16 Tigo Gmbh Anti-gama mutant protein against endogenous human gamma interferon

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
HUT64582A (en) * 1989-11-29 1994-01-28 Synergen Inc Method for producing recombinant human interleukin-1 inhibitor
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
JP3496937B2 (en) * 1990-10-17 2004-02-16 アムジエン・インコーポレーテツド Medical composition containing consensus human interferon for treating cell proliferative disorders
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5858355A (en) * 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
SG47099A1 (en) * 1991-03-15 1998-03-20 Amgen Boulder Inc Pegylation of polypeptides
DK0639079T3 (en) * 1992-04-30 2000-06-13 Amgen Inc Methods for the treatment of interleukin-1 and tumor necrosis factor-mediated diseases
DE69333378T2 (en) * 1992-09-17 2004-07-01 Amgen Inc., Thousand Oaks PHARMACEUTICAL COMPOSITIONS WITH INTERLEUKIN-1 INHIBITORS
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
WO1994020517A1 (en) * 1993-03-08 1994-09-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for treating a connective tissue of a mammalian host
DK0689449T3 (en) * 1993-03-19 2003-03-03 Vacsyn Sa Preparations for use in human therapy, characterized by combining a muramyl peptide with a cytokine
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
FR2706772A1 (en) * 1993-06-22 1994-12-30 Vacsyn Sa Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin.
AU1916295A (en) * 1994-02-08 1995-08-29 Amgen, Inc. Oral delivery of chemically modified proteins

Also Published As

Publication number Publication date
KR20010030563A (en) 2001-04-16
AU741074B2 (en) 2001-11-22
TW474817B (en) 2002-02-01
CN1267225A (en) 2000-09-20
US6013253A (en) 2000-01-11
HK1030157A1 (en) 2001-04-27
EP1003546B1 (en) 2006-09-06
ATE338563T1 (en) 2006-09-15
KR100415636B1 (en) 2004-01-24
CA2299361C (en) 2009-09-29
ES2267188T3 (en) 2007-03-01
PT1003546E (en) 2006-12-29
CA2299361A1 (en) 1999-02-25
CN1183963C (en) 2005-01-12
DK1003546T3 (en) 2006-10-30
IL134345A0 (en) 2001-04-30
HUP0002755A2 (en) 2000-12-28
WO1999008702A1 (en) 1999-02-25
AU8300698A (en) 1999-03-08
HU229045B1 (en) 2013-07-29
JP3813440B2 (en) 2006-08-23
IL134345A (en) 2011-03-31
HUP0002755A3 (en) 2001-11-28
CY1107314T1 (en) 2012-11-21
DE69835823T2 (en) 2007-08-09
JP2001515047A (en) 2001-09-18
EP1003546A1 (en) 2000-05-31

Similar Documents

Publication Publication Date Title
DE69835823D1 (en) METHOD FOR THE TREATMENT OF PATIENTS SUFFERING FROM MULTIPLE SCLEROSIS WITH CONSENSUS INTERFERON
DE69617469D1 (en) TREATMENT OF MULTIPLE Sclerosis
ATE219373T1 (en) MEDICATIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES USING INTERFERON-TAU
DE69616376D1 (en) Use of tiagabin for the treatment of sleep disorders
ATE161192T1 (en) METHOD FOR TREATING A DISORDER MEDIATED BY LFA-1
DE69428523D1 (en) METHOD FOR TREATING MENTAL OR MENTAL DISEASES AND MENTAL OR MENTAL DISEASES ASSOCIATED WITH SEASON
DE69736712D1 (en) PROCESS FOR REDUCING NEUROPATHIC PAIN RELATED TO PROSAPOSIN-RELATED PEPTIDES
DE69703689D1 (en) THERAPEUTIC APPLICATIONS OF BPI PROTEIN PRODUCTS FOR TREATING HUMAN MENINGOCOCCÄMIA
DE69535264D1 (en) METHOD FOR THE TREATMENT OF DIABETES BY KGF
IL161889A0 (en) Method for treating diseases with omega interferon
DE69625682D1 (en) METHOD FOR TREATING IGNITIONS AND COMPOSITIONS THEREFOR
ATE453402T1 (en) USE OF SERP-1 IN COMBINATION WITH AN IMMUNOSUPPRESSOR TO TREAT ARTHRITIS
SE9603725D0 (en) New teatment
DE69837322D1 (en) METHOD FOR THE THERAPEUTIC ADMINISTRATION OF ANTI-CD40L MEDIUM
BR9809678A (en) Triptolyte derivatives useful in the treatment of autoimmune diseases
ATE271879T1 (en) METHOD FOR TREATING AUTOIMMUNE DISEASES USING TYPE 1 INTERFERONS
ATE213163T1 (en) METHOD FOR TREATING MOTOR DEFICIT
DE60144493D1 (en) METHOD FOR THE DETERMINATION AND TREATMENT OF TUBEROUS SCLEROSIS COMPLEX ASSOCIATED DISEASES
ATE249832T1 (en) USE OF OLANZAPINE OR A SALT IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF AUTISM AND MENTAL RETARDATION
ATE295731T1 (en) OLNZAPINE FOR THE TREATMENT OF DRUG ABUSE
DE69307702D1 (en) USE OF (E) - 2 - (P -FLUOROPHENETHYL) - 3 - FLUOROALLYLAMINE FOR TREATING ALZHEIMER'S DISEASE
ATE229343T1 (en) COMBINATION OF TEMOZOLOMIDE AND ALPHA INTERFERON FOR THE TREATMENT OF ADVANCED CANCER
ATE275414T1 (en) METHOD FOR TREATING ENDANGESTITAL DISEASES BY USING CHOLERATOXIN SUBUNIT B
DE69430807D1 (en) METHOD FOR TREATING LIVER DISEASES AND SIMILAR INDICATIONS WITH VASODILATING ACTIVE SUBSTANCES
ATE250416T1 (en) METHOD FOR TREATING AND PREVENTING NEURODEGENERATIVE DISEASES BY ADMINISTRATION OF A THIAZOLIDINE

Legal Events

Date Code Title Description
8364 No opposition during term of opposition